Article
Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
European journal of haematology - 1 Mar 2021
Machnicki Marcin M, Górniak Patryk, Pępek Monika, Szymczyk Agnieszka, Iskierka-Jażdżewska Elżbieta, Steckiewicz Paweł, Bluszcz Aleksandra, Rydzanicz Małgorzata, Hus Marek, Płoski Rafał, Makuch-Łasica Hanna, Nowak Grażyna, Juszczyński Przemysław, Jamroziak Krzysztof, Stokłosa Tomasz, Puła Bartosz
Abstract excerpt
BACKGROUND: Ibrutinib, an inhibitor of the Bruton's kinase (BTK), is characterized by high efficacy in the therapy of patients with relapsed and refractory chronic lymphocytic leukemia (RR-CLL). AIMS: To analyze the potential significance of the mutational status of selected 30 genes on the disease outcome in 45 patients with RR-CLL using custom-made gene panel and sequencing on Illumina MiSeq FGx platform....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.